公开(公告)号：KR100964433B1

公开(公告)日：2010-06-16

申请号：KR1020080110377

申请日：2008-11-07

Applicant: (주)아모레퍼시픽

Inventor： 노민수 ,  여현주 ,  박선미 ,  신동욱 ,  이형호 ,  김한곤

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/158

Abstract: 본 발명은 피부 기능 향상 물질을 스크리닝(screening)하는 방법으로서, (a) 후보 물질을 피부 세포에 처리하는 단계; (b) MAP17(Membrane-Associated Protein 17kD) 유전자의 상대적 발현량 변화를 검출하는 단계; 및 (c) 상기 유전자의 발현량 변화를 유도하는 후보 물질을 피부 기능 향상 물질로 선택하는 단계를 포함한다.
즉, 본 발명은 MAP17(Membrane-Associated Protein 17kD) 유전자를 표지인자로 하여 MAP17 유전자의 발현량 변화를 통해 피부 기능 향상 물질을 검색하는 신규한 스크리닝 방법으로서, 이를 통해 피부 장벽 기능 향상, 피부 보습 유지, 피부 노화 방지 또는 피부 트러블 완화에 유용한 피부 기능 향상 물질을 효율적으로 스크리닝할 수 있다.
MAP17(Membrane-Associated Protein 17kD), 스크리닝

公开(公告)号：KR1020090119159A

公开(公告)日：2009-11-19

申请号：KR1020080045032

申请日：2008-05-15

Applicant: (주)아모레퍼시픽

Inventor： 신동욱 ,  노민수 ,  이형호 ,  이상민 ,  송민정 ,  김한곤

IPC: A61K31/202 ,  A61P3/04

CPC classification number: A61K31/202 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

Abstract: PURPOSE: A pharmaceutical composition for suppressing adipocyte differentiation and reducing lipid droplet is provided to prevent or treat obesity or lipoma. CONSTITUTION: A pharmaceutical composition of adipocyte differentiation contains arachidonyl dopamine. The pharmaceutical composition prevents adipose tissue enlargement-related disease. The adipose tissue enlargement-related disease is obesity or lipoma. The differentiation of adipocyte is from mesenchymal stem cell to adipocyte. The mesenchymal stem cell is human bone marrow mesenchymal stem cell. A formulation of oral administration is used in the form of pill, powder, suspension, emulsion, syrup, and granule.

Abstract translation: 目的：提供抑制脂肪细胞分化和降低脂滴的药物组合物，以预防或治疗肥胖或脂肪瘤。 构成：脂肪细胞分化的药物组合物含有花生四烯多巴胺。 该药物组合物防止脂肪组织扩大相关疾病。 脂肪组织增生相关疾病是肥胖或脂肪瘤。 脂肪细胞的分化是从间充质干细胞到脂肪细胞。 间充质干细胞是人骨髓间充质干细胞。 口服给药的制剂以丸剂，粉剂，悬浮液，乳剂，糖浆剂和颗粒剂的形式使用。

公开(公告)号：KR1020090057834A

公开(公告)日：2009-06-08

申请号：KR1020070124591

申请日：2007-12-03

Applicant: (주)아모레퍼시픽

Inventor： 신동욱 ,  신의석 ,  이형호 ,  이태룡

IPC: C12N15/06 ,  C12N15/09 ,  C12N5/07

Abstract: A method for measuring the activity of transfection cell line and PGC1-alpha promoter is provided to search a material inducing the expression of PGC1-alpha and easily measuring the activity of PGC1-alpha promoter site. A transfection cell line which expresses a PGC1-alpha is transfected by a vector containing human PGC1-alpha promoter, antibiotic resistance gene, and reporter gene. The antibiotic resistance gene has neomycin and kanamycin. The reporter gene is luciferase gene. The vector is plasmid. A method for measuring the activity of PGC1-alpha promoter site comprises: a step of treating a PGC1-alpha promoter regulation material in the transfected cell line; and a step of measuring the activity of reporter gene.

Abstract translation: 提供了一种测量转染细胞系和PGC1-α启动子的活性的方法，以搜索诱导PGC1-α表达的物质，并容易测定PGC1-α启动子位点的活性。 通过含有人PGC1-α启动子，抗生素抗性基因和报道基因的载体转染表达PGC1-α的转染细胞系。 抗生素抗性基因具有新霉素和卡那霉素。 报告基因为萤光素酶基因。 载体是质粒。 测量PGC1-α启动子位点活性的方法包括：处理转染细胞系中PGC1-α启动子调节物质的步骤; 以及测定报道基因的活性的步骤。

公开(公告)号：KR1020090056632A

公开(公告)日：2009-06-03

申请号：KR1020070123865

申请日：2007-11-30

Applicant: (주)아모레퍼시픽

Inventor： 김상훈 ,  조시영 ,  박필준 ,  송민정 ,  이형호 ,  이태룡 ,  김정주 ,  김남수

IPC: C12N15/10 ,  C12N15/09 ,  C12Q1/68

CPC classification number: C12Q1/6876 ,  C12Q2600/158

Abstract: A kit and a method for screening a candidate material which promotes the lipolysis is provided to increase the melanocortin 2 receptor accessory protein(Mrap) gene expression, promote the lipolysis by ACTH(adrenocorticotropic hormone) and prevent and treat the obesity relating disease. A kit for screening a candidate material which promotes the lipolysis comprises a vector containing a promoter and reporter gene. The promoter comprises 842th to 853th bases of the sequence number 1(SEQ ID NO:1) or additional 1569th to 1581th bases thereon. The reporter gene is a luciferase gene, enhanced green fluorescent protein(EGFP) gene, or beta galactosidase(lacZ) gene. A method for screening the candidate material which promotes the lipolysis comprises: a step of transfecting a test cell which is designated to express a PPAR-gamma(peroxisome proliferator-activated receptor-gamma) with the vector; a step of treating with the candidate material in the transfected test cell; and a step of measuring the expression degree of the reporter gene in the test cell and selecting the candidate material.

Abstract translation: 提供用于筛选促进脂肪分解的候选物质的试剂盒和方法以增加黑皮质素2受体辅助蛋白（Mrap）基因表达，促进ACTH（促肾上腺皮质激素）的脂解，并预防和治疗肥胖症相关疾病。 用于筛选促进脂肪分解的候选物质的试剂盒包含含有启动子和报告基因的载体。 启动子包含序列号1（SEQ ID NO：1）的第842位至第853位碱基或其上第1569至1581位碱基。 报告基因是荧光素酶基因，增强型绿色荧光蛋白（EGFP）基因或β半乳糖苷酶（lacZ）基因。 用于筛选促进脂肪分解的候选物质的方法包括：转染被称为用载体表达PPAR-γ（过氧化物酶体增殖物激活受体-γ）的测试细胞的步骤; 在转染的测试细胞中用候选物质处理的步骤; 以及测定测定单元中的报道基因的表达程度并选择候选材料的步骤。

公开(公告)号：KR1020090056611A

公开(公告)日：2009-06-03

申请号：KR1020070123840

申请日：2007-11-30

Applicant: (주)아모레퍼시픽

Inventor： 신의석 ,  이형호 ,  이태룡

IPC: A61K31/105 ,  A61K31/145 ,  A61P3/04

Abstract: A composition containing a compound which suppresses the activation of a glucose-6-phosphate dehydrogenase for inhibiting the adipocyte differentiation is provided to suppress the lipid synthesis and adipocyte differentiation and treat the disorder of lipid metabolism such as obesity and hyperlipidemia. An inhibitor of glucose-6-phosphate dehydrogenase activation is denoted by the chemical formula 1. In the chemical formula 1, X is O or S, R1 is H or C1-6 alkyl, R2 and R3 is individually H or OH. The compound of the chemical formula 1 is 1,3di-(E)-N'-(2,3-dihydroxybenzylidene)thiohydrazide of the chemical formula 1a or (E)-3-(3-ethoxyphenyl)-N'-(2-hydroxy benzylidene)-1H-pyrazole-5-carbohydrazide of the chemical formula 1b. The composition is used in a form of a tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosole, soft or hard gelatin capsule, or sterilization powder.

Abstract translation: 提供含有抑制葡萄糖-6-磷酸脱氢酶活化以抑制脂肪细胞分化的化合物的组合物，以抑制脂质合成和脂肪细胞分化，并治疗诸如肥胖症和高脂血症的脂质代谢紊乱。 葡萄糖-6-磷酸脱氢酶活化的抑制剂由化学式1表示。在化学式1中，X为O或S，R 1为H或C 1-6烷基，R 2和R 3为H或OH。 化学式1的化合物是化学式为1a的1,3-二（E）-N' - （2,3-二羟基亚苄基）硫代酰肼或（E）-3-（3-乙氧基苯基）-N' - （2 - 羟基亚苄基）-1H-吡唑-5-碳酰肼。 组合物以片剂，丸剂，粉末，香囊，酏剂，悬浮液，乳液，溶液，糖浆，气溶胶，软或硬明胶胶囊的形式或灭菌粉末的形式使用。

公开(公告)号：KR1020080051239A

公开(公告)日：2008-06-11

申请号：KR1020060121960

申请日：2006-12-05

Applicant: (주)아모레퍼시픽

Inventor： 신동욱 ,  신의석 ,  이형호 ,  김대건 ,  이정아 ,  윤준원 ,  노호식 ,  백흥수

IPC: A61K31/166 ,  A61K31/045 ,  A61P3/04

Abstract: A pharmaceutical composition comprising compounds capable of increasing expressions of isocitrate dehydrogenase 3alpha(IDH3alpha) and carnitine palmitoyl transferase 1A(CPT1A) by increasing activity of their promoters is provided to reduce synthesis of fatty acid and promote oxidation of fatty acid, so that the composition is useful for treating and preventing lipid metabolism-related diseases. A pharmaceutical composition for treating and preventing lipid metabolism-related diseases comprises compounds represented by the formula(1) in which R1 is adamantly group or phenyl group substituted by H, OH or C1-C5 alkyl, and R2 is CONH or NHCO, and further comprises pharmaceutically acceptable carriers, excipients or diluents selected from lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, crystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

Abstract translation: 提供了包含通过提高其启动子的活性而能够增加异柠檬酸脱氢酶3α（IDH3α）和肉碱棕榈酰转移酶1A（CPT1A）的表达的化合物的药物组合物，用于减少脂肪酸的合成并促进脂肪酸的氧化，使得组合物 用于治疗和预防脂质代谢相关疾病。 用于治疗和预防脂质代谢相关疾病的药物组合物包括由式（1）表示的化合物，其中R1是金刚烷基或被H，OH或C1-C5烷基取代的苯基，R2是CONH或NHCO， 包括药学上可接受的载体，赋形剂或稀释剂，其选自乳糖，葡萄糖，蔗糖，山梨糖醇，甘露糖醇，木糖醇，赤藓糖醇，麦芽糖醇，淀粉，阿拉伯胶，藻酸盐，明胶，磷酸钙，硅酸钙，纤维素，甲基纤维素，结晶纤维素，聚乙烯吡咯烷酮 ，水，羟基苯甲酸甲酯，羟基苯甲酸丙酯，滑石，硬脂酸镁和矿物油。